头颈部鳞状细胞癌 CAR-T 细胞治疗的进展与挑战
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma.
头颈部鳞状细胞癌(HNSCC)仍是最具侵袭性的恶性肿瘤之一,治疗选择有限,尤其是在复发和转移性病例中。
ALL SOURCES
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma.
头颈部鳞状细胞癌(HNSCC)仍是最具侵袭性的恶性肿瘤之一,治疗选择有限,尤其是在复发和转移性病例中。
NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors.
NR4A因子通过线粒体基因表达调控CAR-T细胞的持久性和干性,因此NR4A是生成针对实体瘤的优质CAR-T细胞的高度有前景的靶点。
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition.
实体瘤的嵌合抗原受体(CAR)-T 细胞疗法面临重大障碍,包括由 PD-1/PD-L1 轴介导的 T 细胞抑制。
Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.
卵巢癌(OC)仍是最致命的妇科恶性肿瘤,其特征为诊断晚、肿瘤异质性和化疗耐药,导致生存率低。
Single-hit genome editing optimized for maturation in B cells redirects their specificity toward tumor antigens.
基于T细胞的过继性免疫治疗是癌症治疗的新支柱。
共 5 条
MEMBER ACCOUNT
登录成功会直接打开下一页。